Where results make sense

About us   |   Why use us?   |   Reviews   |   PR   |   Contact us

E-Marcom Inc. - Case Studies: Allergan Allergan was looking to improve the feedback mechanisms used in their marketing campaigns. Allergan has been able to receive data on how their target market of physicians views Allergan’s marketing materials and the effectiveness of the campaign. Allergan is able to determine, more precisely than with traditional customer feedback tools, the actual behavior patterns of doctors and patients. www.e-marcom.net /emarcom_static/cs_allergan.html   (130 words)

Allergan In a detailed affidavit filed December 10, 2004 in U.S. Federal District Court in San Jose, California, the Office of Criminal Investigations of the FDA indicates that the cases of botulism resulted from the illegal administration of enormous amounts of unlicensed and unapproved botulinum toxin by an unlicensed physician in Florida. Allergan's own calculations indicate that the vial may have contained as much as 10 million units of botulinum toxin. Allergan develops and commercializes products in the eye care, neuromodulator, skin care and other specialty markets that deliver value to its customers, satisfy unmet medical needs, and improve patients' lives. www.shareholder.com /agn/ReleaseDetail.cfm?ReleaseID=150344   (788 words)

Allergan - Sterling Commerce   (Site not responding. Last check: 2007-11-02) Once the reorganization was complete, electronic commerce became critical to Allergan, and the company began to see electronic commerce as the central focus to helping the business move from a decentralized database structure into an integrated system. Allergan prides itself on its strong customer service strategy to guarantee customer orders received will be delivered within a specific time period. Allergan's first priority at the moment is to implement Germany and then migrate existing systems in Spain and Italy. www.sterlingcommerce.com /About/SuccessStories/allergan.htm   (964 words)

Allergan Horizon Grant The purpose of the Allergan Horizon Fellowship Grant Program is to advance the practice of ophthalmology by supporting academic medical institution fellowship programs. Allergan recognizes the important role fellows play in contributing to ophthalmology research and development. Allergan will contribute $1 million over two years toward the development and implementation of the Horizon Grant Program. www.allerganhorizongrants.com   (267 words)

Business Objects Selected by Allergan for Global Enterprise Deployment Allergan, which develops and distributes products designed to treat specific diseases such as glaucoma, movement disorders, psoriasis, and acne, will use Business Objects to power its corporate reporting system, which will be rolled out to more than 2,500 employees globally over the next two and a half years. Allergan relies on its information to be correct, timely, complete, and consistent and quick access to that data is crucial. Allergan develops and commercializes products in the eye care pharmaceutical, ophthalmic surgical device, over-the-counter contact lens care, movement disorder, and dermatological markets that deliver value to our customers, satisfy unmet medical needs, and improve patients' lives. www.businessobjects.com /news/press/press2001/allergan.asp   (687 words)

Allergan :: About Allergan When Allergan decided to expand internationally in the 1970s the UK and Ireland became a new major focus. Allergan develops and markets a broad range of therapeutic eye care products targeting a variety of diseases. Allergan develops and markets a therapeutic muscle-relaxing agent that works at motor nerve endings (nerves that lead to muscles). www.allergan.co.uk /site/about/home.asp?id=&largeText=   (447 words)

Allergan Canada Inc. :: Neuromuscular Home Page Allergan has been the world leader in botulinum neurotoxin therapy for the past 15 years. This leadership has been based on BOTOX® and the expanding number of conditions for which it is used. The expanding clinical uses of BOTOX® are due to the same properties that made it beneficial for those first patients: potent, localized action on specific peripheral nerve cells coupled with an excellent safety profile and low antigenic potential. www.allergan.ca /site/neuromuscular/home.asp?largeText=no   (92 words)

The Allergan Foundation donates $2 million to advance eye research and treatment   (Site not responding. Last check: 2007-11-02) Allergan develops and commercializes products in the ophthalmology, neurosciences, dermatology, medical aesthetics and other specialty markets that deliver value to its customers, satisfy unmet medical needs, and improve patients' lives. Allergan has been a world leader in ophthalmology for more than half a century, with products focused around treatments for glaucoma, ocular allergy and infections, retinal disease and dry eyes. Created in 1998, The Allergan Foundation is dedicated to making a lasting and positive impact on the communities and neighborhoods that its employees call home, in partnership with those whose philanthropic endeavors match Allergan's specialties and areas of research interest. www.eurekalert.org /pub_releases/2006-05/uoc--taf050806.php   (794 words)

The Allergan Foundation Donates $2 Million to Advance Eye Research and Treatment, May 2006, UCI Medical Center News ... Allergan has one of the broadest product pipelines of any company pursuing retinal therapeutics, and also continues to pursue novel treatments for glaucoma and dry eye disease. A major focus of Allergan's research and development pipeline is on back-of-the-eye diseases such as macular edema, diabetic retinopathy and age-related macular degeneration, the leading cause of blindness in developed countries. In addition, Allergan is supporting the world's largest Phase III clinical trial to investigate the potential use of a neuroprotective compound for the treatment of glaucoma. www.ucihealth.com /News/Releases/06MayAllerganDonates.htm   (807 words)

Inamed, a division of Allergan: Press Release Archive   (Site not responding. Last check: 2007-11-02) Allergan expects to amend the terms of its exchange offer to conform to the terms specified in the definitive merger agreement promptly by making all requisite filings with the SEC. Allergan develops and commercializes products in the ophthalmology, neurosciences, medical dermatology, medical aesthetics and other specialty markets that deliver value to its customers, satisfy unmet medical needs, and improve patients' lives. Allergan has filed a Registration Statement on Form S-4 and a Tender Offer Statement on Schedule TO in connection with the exchange offer, and from time to time may file amendments or supplements to such filings. www.allerganandinamed.com /media/archive2006/20051220.html   (1145 words)

Allergan Allergan's print output continues to be under safe watch from HP Output Server Allergan urgently needed to address the output issues before important business functions were crippled and employee confidence in the newly implemented ERP system was lost. To accomplish this, Allergan's strategy was to create a corporate repository for transaction information, on a single SAP R/3 instance, located at its Irvine, California headquarters. h20247.www2.hp.com /PublicSector/cache/97494-0-0-205-399.html   (1060 words)

RTE Business - 325 Allergan jobs in Co Mayo to go The Allergan Pharmaceutical company in Westport, Co Mayo has announced that it is to lay off 325 workers out of its total work force of more than 900. Allergan makes solutions for contacts lenses and it also manufactures Botox, which is used in cosmetic facial procedures and for the treatments of therapeutic neuromuscular disorders. It said this decision was taken in 2002 to enable Allergan to focus on its core high growth businesses in specialty pharmaceuticals. www.rte.ie /business/2004/1101/jobs.html   (294 words)

News: Allergan Integrates Inamed's Commercial and Research and Development Operations within New Corporate Division, ... Allergan, Inc. (NYSE:AGN) today announced it has completed the integration of Inamed's commercial and research and development operations, uniting the companies' facial aesthetics, breast aesthetics and obesity intervention product portfolios under the Allergan name and within a newly established corporate division, Allergan Medical. While Allergan's headquarters remain in Irvine, CA, the company is retaining a presence in Santa Barbara, CA, where it will maintain a national center of excellence focused on medical aesthetics research and development, customer and patient service, and quality assurance. Allergan Medical also offers the industry's widest range of breast implant options for reconstructive and aesthetic breast surgery, and leading minimally invasive devices for obesity intervention treatment. www.genengnews.com /news/bnitem.aspx?name=6538837   (607 words)

Allergan   (Site not responding. Last check: 2007-11-02) Allergan already submits some of its documentation electronically, but the sooner it can meet this forthcoming requirement, the sooner the company can eliminate the costs of printing and shipping paper documentation. Authors at Allergan’s headquarters can create chunks of content that are then stored in a “base cabinet” from which the various regions can select what they want to include and translate on their respective Web sites. Allergan is also in the process of moving its Documentum RandD and manufacturing systems to an intranet client using Documentum Document Control Manager. software.emc.com /about_us/customer/profiles/allergan.htm   (1332 words)

[No title]   (Site not responding. Last check: 2007-11-02) Dendrite's solution offers Allergan a Web-based, synchronized, communication channel that allows for the seamless passage of vital information in real time, enabling product representatives to be more effective in serving their customers. Allergan, Inc., headquartered in Irvine, California, is a technology-driven global healthcare company providing eye care and specialty pharmaceutical products worldwide. Allergan develops and commercializes products in the eye care pharmaceutical, ophthalmic surgical device, over-the-counter contact lens care, movement disorder, and dermatological markets that deliver value to its customers, satisfying unmet medical needs, and improving patients' lives. www.dendrite.com /index.aspx?page_id=225   (378 words)

Upside From New Products At Allergan - Forbes.com   (Site not responding. Last check: 2007-11-02) Maris said the recent approval and pending European launch of Ganfort, used to treat glaucoma, and the pending approval of new silicone breast implants and the anti-wrinkle injection treatment Juvederm could prove to be growth catalysts for Allergan (nyse: AGN - news - people) stock. As for Allergan's breast-implant products, there is a risk that they won't receive approval or that Allergan's competitor, Mentor, could receive first or even sole approval, Maris warned. But if Allergan's products are approved, the company could capture profits from the higher demand for silicone implants in 2007, which, according to trends in Europe, are likely to be priced at approximately two times the cost of saline implants. www.forbes.com /2006/06/05/allergan-0605markets03.html?partner=alerts   (383 words)

Allergan's RESTASIS(TM) Approved by the FDA; The First And Only Therapeutic Treatment To Increase Tear Production In ... Allergan estimates that RESTASIS(TM) will be launched in the second quarter of 2003 and given the anticipated launch costs and royalties on the product, the profit impact in 2003 is expected to be modest. Copies of Allergan press releases and additional information about Allergan are available on the World Wide Web at www.allergan.com, or you can contact the Allergan Investor Relations Department at 714/246-4636. Allergan develops and commercializes products in the eye care, neuromodulator and skin care markets that deliver value to our customers, satisfy unmet medical needs, and improve patients' lives. www.allergan.de /site/investors/pr_details.asp?id=98296   (798 words)

FTC Clears Allergan Merger   (Site not responding. Last check: 2007-11-02) Allergan (AGN - news - Cramer's Take) said Wednesday that it received approval from the Federal Trade Commission to complete its takeover of Inamed (IMDC - news - Cramer's Take). The FTC said Wednesday that Allergan's acquisition of Reloxin, which is still in clinical trials, "likely would reduce competition and force consumers to pay higher prices" for wrinkle creams based on the botulism toxin. Shares of Allergan were up $2.45, or 2.2%, to $112.90, while Inamed gained $1.33, or 1.5%, to $90.75. www.thestreet.com /stocks/medicalservices/10272555.html   (348 words)

Allergan Inc. (Product development) | Business solutions from AllBusiness.com Allergan is set to break ground on a 172,000-square-foot,... Allergan Inc. is banking on other uses for its flagship Botox drug as well as new products to keep up the growth that's made the... Irvine's Allergan Inc. is set to pounce on its second sizable acquisition this year. www.allbusiness.com /allergan-inc/3246524-1.html   (779 words)

Israel: Allergan v. B4U—Trademark Infringement In a decision of the Israeli District Court dated January 12, 2005, in the framework of provisional proceedings in the matter of C.A. Allergan, Inc. et al., v. Applicant No. 1, Allergan, Inc. ("Allergan"), is the owner of the well-known trademark "BOTOX" ("the BOTOX Mark"), which is also registered in Israel in class 5 with respect to, inter alia, pharmaceutical preparations for the treatment of wrinkles. Allergan and its Israeli distributor filed a claim, as well as an application for provisional orders, against the respondents, on the grounds of infringement of the BOTOX Mark (as well as on other grounds, including passing-off, dilution of trademark, unlawful enrichment, etc. www.cafezine.com /printtemplate.asp?id=2047   (732 words)

Allergan   (Site not responding. Last check: 2007-11-02) With more than 55 years of experience providing high-quality, science-based products, Allergan, Inc., with headquarters in Irvine, California, discovers, develops and commercializes products in the ophthalmology, neurosciences, medical dermatology, medical aesthetics, obesity intervention and other specialty markets that deliver value to its customers, satisfy unmet medical needs, and improve patients' lives. Devoting more than 10% of our sales to research and development, Allergan seeks to use proprietary technology to develop unique pharmaceutical products that create value and achieve a sustainable competitive advantage. R&D efforts are focused in the disease areas of glaucoma/neuroprotection, retinal disease, cataracts and dry eye; skin disorders such as psoriasis, acne and photodamaged skin; and other diseases such as movement disorders, pain and cancer. company.monster.com /allerg   (136 words)

Allergan Jobs: Vault Jobs & Employment Profiles   (Site not responding. Last check: 2007-11-02) Today, Allergan, Inc. is a technology- and research-driven global health care company offering specialty pharmaceutical products. Allergan, headquartered in Irvine, Calif., develops and markets products in ophthalmology, neurosciences, medical dermatology, medical aesthetics and other specialty markets, and has global sales and marketing capabilities wi...... Allergan employee surveys are collected by Vault editors, Vault Gold Surveys provide detailed information on jobs and employment at specific employers. www.vault.com /jobs-company/Allergan.html   (289 words)

Inspire Pharmaceuticals, Inc. - Our Partnerships In December 2002, Restasis was approved for sale by the FDA and Allergan launched Restasis in the United States in April 2003. Allergan records sales of Elestat and remains responsible for all other product costs, as well as retaining responsibility for all international marketing and selling activities. Allergan is responsible for supply chain management, managed healthcare, customer order processing and regulatory compliance. www.inspirepharm.com /partners.html   (676 words)

Preserving Competition, FTC Requires Divestiture Before AllowingAllergan’s Acquisition of Inamed The FTC alleges that Allergan’s purchase of the expected first serious competitor to Botox likely would reduce competition and force consumers to pay higher prices for the botulinum toxin type A products used by millions of Americans to temporarily erase frown lines and wrinkles. Allergan’s Botox is the best-selling botulinum toxin in the United States and the only such product approved by the U.S. Food and Drug Administration for the treatment of facial wrinkles. Today, Allergan’s Botox dominates the U.S. market for botulinum toxins and is the only one approved by the FDA to treat facial wrinkles. www.ftc.gov /opa/2006/03/allergan.htm   (963 words)

News: Allergan, Inc. Announces Launch of JUVEDERM(TM) ULTRA and JUVEDERM(TM) ULTRA PLUS. Genetic Engineering News - ... Allergan, Inc. (NYSE:AGN), the maker of BOTOX(R) Cosmetic (Botulinum Toxin Type A), today announced it is launching its 'next-generation' hyaluronic acid dermal filler products, JUVEDERM(TM) ULTRA and JUVEDERM(TM) ULTRA PLUS, through an experience trial involving a group of physicians with expertise in facial aesthetics, in advance of nationwide product availability in January 2007. Allergan will begin accepting physician pre-orders for the products on November 1, 2006 via its nationwide sales force. Additional information concerning these and other risk factors can be found in press releases issued by Allergan, as well as Allergan's public periodic filings with the Securities and Exchange Commission, including the discussion under the heading "Risk Factors" in Allergan's 2005 Form 10-K and Allergan's Form 10-Q for the quarter ended June 30, 2006. www.genengnews.com /news/bnitem.aspx?name=6092992   (1402 words)

Allergan: Smoothing the Wrinkles Still, Allergan's stock has dropped about 6% since then, to $107.17, largely on concerns that sales of its most famous product, the wrinkle reducer Botox Cosmetic, may be slowing. Allergan CEO David E.I. Pyott sat down with BusinessWeek's Arlene Weintraub to discuss Botox, as well as other areas that are driving Allergan's growth. But it's injected in the forehead (as is the wrinkle-reducing form), so at first managed-care companies reacted by saying, "I'm not going to pay to treat people's wrinkles." Then they found out that the cost of the treatment only amounts to about $1.20 a day, and their attitude went from "no thanks" to tremendous enthusiasm. www.businessweek.com /technology/content/feb2006/tc20060209_647643.htm   (1281 words)

Allergan :: India Allergan Inc with headquarters in Irvine, California, is a global corporation devoted to continuous innovation in Specialty pharmaceuticals. Based in Bangalore, Allergan India Ltd. began operations in 1996 and within three years established itself as a Leader in ophthalmology. A joint venture of Allergan Inc. and Nicholas Piramal (I) Ltd. the company has a nation-wide distribution channel supplying Eyecare Pharmaceutical, Surgical and Optical products. www.allergan.co.in   (117 words)

Allergan Press Release Allergan's own calculations indicate that the vial may have contained as much as Allergan has a number of measures in place to ensure the integrity and authenticity of BOTOX Allergan encourages both physicians and consumers to visit its web sites at www.Allergan.com, www.BOTOX.com and www.BOTOXCosmetic.com to learn more about BOTOX® and BOTOX® Cosmetic. www.agedefy.com /p/p.asp?mlid=153   (922 words)

Try your search on: Qwika (all wikis)

About us   |   Why use us?   |   Reviews   |   Press   |   Contact us   Copyright © 2005-2007 www.factbites.com Usage implies agreement with terms.